A Research Guide for Facing Diffuse Large B-Cell Lymphoma
Understanding DLBCL, diagnosis, staging, first-line treatment, relapsed/refractory options including CAR-T and bispecific antibodies, clinical trials, supportive care, and practical resources — organized by where you are in the journey.
This guide is not medical advice. It is an educational research summary written in plain language, drawn from published medical literature and clinical trial records. Every important decision must be made together with the patient’s medical team — hematologist-oncologists, transplant physicians, and primary care doctors. Nothing here replaces those conversations. The purpose of this guide is to help patients and families walk into those conversations better prepared. This content does not create a doctor-patient relationship. Trouvera’s guides are produced using AI-assisted research synthesis with human editorial review; it is not written by treating physicians. Laws regarding medical information vary by jurisdiction; consult a local licensed professional for advice specific to your situation.
Standard care first. Every option discussed in this guide is intended as an addition to, not a replacement for, evidence-based standard treatments delivered by a qualified hematology-oncology team. DLBCL treatment requires coordination between medical oncologists, radiation oncologists, and often transplant specialists.
DLBCL is curable. Unlike many cancers, approximately 60% of DLBCL patients are cured with first-line treatment. Even patients who relapse now have transformative options including CAR-T cell therapy and bispecific antibodies. There is genuine reason for hope.
Content last reviewed: 16 June 2026 · Based on NCCN B-Cell Lymphomas Guidelines v2.2026, ESMO Clinical Practice Guidelines for DLBCL, BSH Guidelines, Lugano Classification, major clinical trials (POLARIX, ZUMA-7, TRANSFORM, EPCORE NHL-1, PILOT, frontMIND), and published medical literature · Always verify trial availability and treatment details with your medical team and primary sources.
⚡ Quick Start — If You Read Nothing Else
The 8 most important things to know right now.
DLBCL is the most common aggressive lymphoma — and it is often curable. Approximately 60% of patients are cured with first-line treatment. This is an aggressive cancer, but the word “aggressive” also means it responds strongly to treatment.
R-CHOP has been the standard treatment for 20+ years. The combination of rituximab plus CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) given every 21 days for 6 cycles remains the backbone of DLBCL treatment worldwide.
Pola-R-CHP is a new first-line option for some patients. The POLARIX trial showed that replacing vincristine with polatuzumab vedotin (pola-R-CHP) improved progression-free survival compared to R-CHOP in patients with IPI score 2–5. This is now an NCCN-preferred option for higher-risk patients.
If first-line treatment fails, CAR-T cell therapy has changed the game. Three FDA-approved CAR-T products (axicabtagene ciloleucel, lisocabtagene maraleucel, tisagenlecleucel) can now be used in the second-line setting, producing durable remissions in approximately 40% of patients.
Bispecific antibodies are a major new option for relapsed disease. Glofitamab (Columvi) and epcoritamab (Epkinly) are FDA-approved “off-the-shelf” treatments that redirect your own immune cells to attack lymphoma, without the complexity of CAR-T manufacturing.
PET scans guide treatment decisions. An interim PET scan after 2–4 cycles and an end-of-treatment PET scan determine whether treatment is working and what comes next.
Cell-of-origin matters. DLBCL is divided into germinal center B-cell (GCB) and activated B-cell (ABC/non-GCB) subtypes. ABC-type tends to have worse outcomes with R-CHOP. Your pathology report should identify this.
Get to a lymphoma specialist. DLBCL treatment is relatively standardized for first-line, but decisions about relapsed disease, CAR-T eligibility, and bispecific antibody selection require lymphoma expertise. A second opinion from an academic center is strongly recommended if you relapse.
▼ Collapse
Understanding Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is a cancer of the lymphatic system — specifically of B lymphocytes, a type of white blood cell that normally helps fight infection. In DLBCL, these B cells acquire mutations that cause them to grow rapidly and form tumors, most commonly in lymph nodes but also in organs like the stomach, intestines, brain, bones, or skin.
DLBCL is called “diffuse” because the abnormal cells are spread throughout the tissue rather than forming distinct clusters. “Large” refers to the size of the cancer cells under a microscope. It is the most common type of non-Hodgkin lymphoma (NHL), accounting for approximately 30% of all NHL diagnoses.
The defining characteristic of DLBCL is that it is aggressive but potentially curable. Unlike indolent (slow-growing) lymphomas that may be watched for years before treatment, DLBCL requires prompt treatment. The upside is that aggressive lymphomas respond strongly to chemotherapy and immunotherapy, and the majority of patients who achieve complete remission after first-line treatment are cured.
Approximately 30,000 new cases per year in the United States
The most common subtype of non-Hodgkin lymphoma (~30% of all NHL)
Median age at diagnosis is approximately 65–70 years, but can occur at any age
Slightly more common in men than women
Incidence is rising in many countries, partly due to aging populations and improved diagnostics
DLBCL is not one disease. Important subtypes include:
DLBCL, NOS (not otherwise specified): The most common form, accounting for ~85% of cases. Further divided by cell-of-origin into GCB and ABC subtypes.
Primary mediastinal large B-cell lymphoma (PMBCL): Arises in the thymus, typically affecting young adults (especially women in their 20s–30s). Often presents with a large chest mass. Has a distinct biology and excellent prognosis with appropriate treatment.
High-grade B-cell lymphoma (HGBCL): Includes “double-hit” lymphomas with MYC and BCL2 and/or BCL6 rearrangements. More aggressive and often requires intensified treatment (e.g., DA-EPOCH-R).
Transformed DLBCL: Arises from a prior indolent lymphoma (usually follicular lymphoma) that has transformed into an aggressive form. Treatment approach differs from de novo DLBCL.
Primary CNS lymphoma: DLBCL arising in the brain. Requires methotrexate-based treatment that crosses the blood-brain barrier.
T-cell/histiocyte-rich large B-cell lymphoma: A rare variant with abundant background T cells and histiocytes.
The most important concept in this guide: DLBCL is curable in approximately 60% of patients with first-line treatment. Even for the ~40% who relapse or are refractory, transformative new therapies — CAR-T cells and bispecific antibodies — are producing durable responses. The treatment landscape for relapsed DLBCL has fundamentally changed since 2020.
Key Breakthroughs in DLBCL
Several major advances have transformed DLBCL management in recent years:
FDA-APPROVED The POLARIX trial was the first to show a significant improvement over R-CHOP in frontline DLBCL in over 20 years. Pola-R-CHP replaces vincristine with polatuzumab vedotin, an antibody-drug conjugate targeting CD79b. In patients with IPI score 2–5, pola-R-CHP reduced the risk of disease progression, relapse, or death by 27% compared to R-CHOP. This is now an NCCN Category 1 preferred option for higher-risk patients.
FDA-APPROVED CAR-T (chimeric antigen receptor T-cell) therapy was initially approved for heavily pretreated DLBCL. The ZUMA-7 and TRANSFORM trials then showed that CAR-T is superior to salvage chemotherapy plus autologous transplant in the second-line setting. Axicabtagene ciloleucel (Yescarta) and lisocabtagene maraleucel (Breyanzi) are now FDA-approved for DLBCL that relapses within 12 months of, or is refractory to, first-line treatment. Approximately 40% of patients who receive CAR-T achieve durable remissions.
FDA-APPROVED Bispecific antibodies are a new class of treatment that simultaneously binds to CD20 on lymphoma cells and CD3 on T cells, redirecting the patient’s own immune system to attack the cancer. Two are FDA-approved for relapsed/refractory DLBCL:
Glofitamab (Columvi): A fixed-duration treatment given as a series of infusions over ~8.5 months. Achieves complete remission in approximately 39% of heavily pretreated patients.
Epcoritamab (Epkinly): A subcutaneous injection given on a schedule that starts weekly, then every 2 weeks, then monthly. Achieves complete remission in approximately 38% of patients.
Unlike CAR-T, bispecific antibodies are available “off the shelf” without the need for cell manufacturing, making them more widely accessible.
FDA-APPROVED 2025 In February 2025 the FDA approved the combination of brentuximab vedotin (Adcetris) + lenalidomide + rituximab for relapsed or refractory large B-cell lymphoma after at least two prior lines of treatment, in patients who are not candidates for a stem-cell transplant or CAR-T therapy. In the phase 3 ECHELON-3 trial it was the first regimen in this hard-to-treat group to show people lived longer (median overall survival about 13.8 vs. 8.5 months versus placebo plus lenalidomide and rituximab). It gives an effective, off-the-shelf option to patients who have run out of, or cannot access, transplant and CAR-T. Notably, it worked regardless of whether the lymphoma carried the CD30 marker that brentuximab targets.
FDA-APPROVED Loncastuximab tesirine is an antibody-drug conjugate targeting CD19 on lymphoma cells. It delivers a potent cytotoxic payload (a pyrrolobenzodiazepine dimer) directly to CD19-expressing cells. FDA-approved for relapsed/refractory large B-cell lymphoma after two or more prior lines of therapy. It achieved an overall response rate of approximately 48% in heavily pretreated patients.
FDA-APPROVED Tafasitamab (Monjuvi) is an anti-CD19 antibody given in combination with lenalidomide for relapsed/refractory DLBCL in patients who are not eligible for autologous transplant. The L-MIND trial showed durable responses in a subset of patients. However, its role in the relapsed setting has been challenged by the arrival of bispecific antibodies and broader CAR-T access. Notably, the Phase 3 frontMIND trial (presented June 2026) tested adding tafasitamab and lenalidomide to R-CHOP as first-line treatment for higher-risk DLBCL and improved progression-free survival; this first-line use is investigational and not yet FDA-approved (see Clinical Trials).
Diagnosis: The Tests You Need
DLBCL diagnosis requires a tissue biopsy — not just a blood test or imaging scan. The biopsy provides the definitive diagnosis, determines the subtype, and identifies critical features that guide treatment.
An excisional biopsy (removing an entire lymph node) is preferred because it provides the most tissue for analysis. If that is not feasible, a core needle biopsy (multiple passes with a large-bore needle) is acceptable. Fine-needle aspiration (FNA) alone is NOT sufficient to diagnose DLBCL because it does not preserve the tissue architecture needed for accurate classification.
IHC uses antibodies to identify specific proteins on the surface and inside of lymphoma cells. Key markers for DLBCL include:
CD20: Positive in virtually all DLBCL — this is the target for rituximab
CD19: Positive — target for CAR-T therapy and some antibody-drug conjugates
CD10, BCL6, MUM1 (IRF4): Used to determine cell-of-origin (Hans algorithm: GCB vs. non-GCB/ABC)
MYC and BCL2 protein expression: “Double-expresser” lymphomas (MYC+/BCL2+ by IHC) have worse prognosis with R-CHOP
Ki-67: Proliferation marker — typically high in DLBCL (>80%)
FISH testing is essential to identify chromosomal rearrangements that define high-grade B-cell lymphoma:
MYC rearrangement: Found in ~10% of DLBCL. If present, must also check for BCL2 and BCL6 rearrangements.
MYC + BCL6 (without BCL2): More controversial. Managed as DLBCL by many centers.
Why it matters: If your lymphoma has a “double-hit” or “triple-hit” profile, the standard R-CHOP regimen may not be sufficient, and your oncologist may recommend intensified treatment such as DA-EPOCH-R.
PET/CT (positron emission tomography/computed tomography) is the standard imaging study for DLBCL staging and response assessment. DLBCL is avidly FDG-avid (PET-positive), making PET an excellent tool for:
Identifying all sites of disease at diagnosis (staging)
Assessing response during and after treatment (interim and end-of-treatment PET)
Detecting relapse during surveillance
Responses are scored using the Deauville 5-point scale: scores 1–3 are generally considered a complete metabolic response (good), while scores 4–5 indicate residual active disease.
A bone marrow biopsy is performed to determine if lymphoma has spread to the bone marrow (stage IV disease). However, if a PET/CT scan shows diffuse bone marrow involvement consistent with lymphoma, some centers now omit the bone marrow biopsy. If the PET is negative in the marrow, a biopsy may still be considered because PET can miss small-cell or discordant low-grade involvement.
Key question for your oncologist: “Has FISH testing been done for MYC, BCL2, and BCL6 rearrangements? What is my cell-of-origin subtype? Is this standard DLBCL, or is it a high-grade B-cell lymphoma that needs intensified treatment?”
Staging — The Lugano Classification
DLBCL staging uses the Lugano Classification (2014), which is based on the older Ann Arbor system. Staging determines where the lymphoma is in your body and helps guide treatment decisions.
Stage
What It Means
Treatment Implications
I
Single lymph node region or single extranodal site
Two or more lymph node regions on the same side of the diaphragm
Limited stage (non-bulky) or advanced stage (bulky). Treatment depends on bulk and IPI score.
III
Lymph node regions on both sides of the diaphragm
Advanced stage. 6 cycles of chemoimmunotherapy.
IV
Widespread involvement of extranodal organs (bone marrow, liver, lungs, etc.)
Advanced stage. 6 cycles of chemoimmunotherapy. Consider CNS prophylaxis if risk factors present.
Important: Unlike solid tumors, stage alone does not determine prognosis in DLBCL. The IPI score (see below) is a better predictor of outcome. A stage IV DLBCL patient with a low IPI score may have excellent outcomes, while a stage II patient with multiple adverse IPI factors may face a greater challenge.
IPI Risk Score — Predicting Outcomes
The International Prognostic Index (IPI) is a scoring system that predicts outcomes in DLBCL. It uses five easily measured factors. Each factor present adds 1 point.
Factor
Adverse = 1 Point
Age
>60 years
Ann Arbor Stage
Stage III or IV
Serum LDH
Above normal
ECOG Performance Status
2, 3, or 4 (limited activity)
Extranodal Sites
>1 extranodal site
IPI Score
Risk Group
Approximate 5-Year OS (R-CHOP era)
0–1
Low
~80–90%
2
Low-Intermediate
~65–75%
3
High-Intermediate
~50–60%
4–5
High
~40–50%
Important: IPI scores reflect historical outcomes with R-CHOP. Newer therapies (pola-R-CHP, CAR-T, bispecific antibodies) are improving outcomes across all risk groups. An IPI score of 4–5 does not mean cure is impossible — it means the road may be harder and more options should be explored early.
Cell-of-Origin Subtypes
DLBCL is classified into subtypes based on which stage of B-cell development the cancer most resembles. This is called “cell-of-origin” (COO) classification and can be determined by gene expression profiling or approximated by IHC using the Hans algorithm.
GCB-type DLBCL arises from cells in the germinal center of the lymph node, where B cells normally undergo maturation. GCB-type tends to have better outcomes with R-CHOP. It frequently carries BCL2 rearrangements and EZH2 mutations.
ABC-type DLBCL arises from B cells that have exited the germinal center and are activating. ABC-type tends to have worse outcomes with R-CHOP. It is characterized by constitutive NF-kB pathway activation and frequently carries MYD88 and CD79B mutations. Multiple trials have attempted to improve outcomes for ABC-type DLBCL by adding targeted agents (ibrutinib, lenalidomide) to R-CHOP, but none have shown definitive benefit in randomized trials.
What is my exact diagnosis? Is this DLBCL NOS, high-grade B-cell lymphoma, or another subtype?
Has FISH testing been done for MYC, BCL2, and BCL6 rearrangements?
What is my cell-of-origin subtype (GCB vs. ABC)?
Is it a “double-expresser” or “double-hit” lymphoma?
What is my stage and IPI score?
Is there any evidence of CNS involvement, and am I at risk for CNS relapse?
Does my treatment plan need to be modified based on any of these features?
Should I get a second opinion at an academic lymphoma center?
First-Line Treatment
First-line treatment for DLBCL is chemoimmunotherapy — chemotherapy combined with the anti-CD20 monoclonal antibody rituximab. The goal is complete remission and cure.
STANDARD OF CARE R-CHOP is given every 21 days (3-week cycles). Each cycle involves:
R — Rituximab: An anti-CD20 antibody given by IV infusion. Targets CD20 on lymphoma cells.
C — Cyclophosphamide: An alkylating agent given IV.
H — Doxorubicin (Hydroxydaunorubicin): An anthracycline given IV. Lifetime cumulative dose limit due to cardiac risk.
O — Vincristine (Oncovin): A vinca alkaloid given IV. Causes peripheral neuropathy.
P — Prednisone: A corticosteroid taken orally for 5 days.
Number of cycles:
Limited stage (I–II, non-bulky): 3–4 cycles of R-CHOP, often followed by involved-site radiation therapy (ISRT). Some centers use 6 cycles without radiation.
Advanced stage (III–IV, or bulky stage II): 6 cycles of R-CHOP.
R-CHOP cures approximately 60% of patients overall, with higher cure rates (80–90%) for low-risk patients.
FDA-APPROVED The POLARIX trial (NCT03274492) compared pola-R-CHP to R-CHOP in 879 previously untreated DLBCL patients with IPI score 2–5. Key results:
2-year PFS: 76.7% vs. 70.2% (HR 0.73, p=0.02) — a 27% reduction in the risk of progression, relapse, or death
Overall survival: no significant difference at the time of analysis (both arms had ~88% 2-year OS)
The benefit was seen primarily in patients with ABC/non-GCB subtype and IPI 3–5
How it differs from R-CHOP: Vincristine is replaced by polatuzumab vedotin (Polivy), an antibody-drug conjugate that delivers the cytotoxic agent MMAE specifically to CD79b-expressing lymphoma cells. The rest of the regimen (rituximab, cyclophosphamide, doxorubicin, prednisone) remains the same. Polatuzumab is given for 6 cycles, with rituximab alone given for cycles 7–8.
Key difference in side effects: Pola-R-CHP causes less peripheral neuropathy than R-CHOP (because vincristine is removed) but somewhat more cytopenias (low blood counts).
GUIDELINE-SUPPORTED Dose-adjusted EPOCH-R is an intensified regimen used for high-grade B-cell lymphoma with MYC and BCL2 rearrangements (“double-hit”). It involves continuous infusion of etoposide, doxorubicin, and vincristine over 96 hours, plus cyclophosphamide, rituximab, and prednisone. Each cycle requires 4 days of continuous IV infusion, typically through a central line.
DA-EPOCH-R has shown improved outcomes compared to R-CHOP for double-hit lymphoma in retrospective studies, and is recommended by NCCN for this subtype. The regimen requires close monitoring and dose adjustments based on blood count recovery.
For patients over 80 years old or with significant comorbidities that preclude standard-dose R-CHOP, dose-reduced “mini-R-CHOP” is an option. This regimen reduces the doses of all chemotherapy agents while maintaining rituximab at full dose. While cure rates are lower, many elderly patients achieve remission and prolonged disease control.
Central nervous system (CNS) relapse is uncommon (~5%) but devastating. Patients at higher risk may receive CNS prophylaxis with intrathecal methotrexate or high-dose IV methotrexate. Risk factors for CNS relapse include:
IPI score 4–5
Involvement of specific sites: kidneys, adrenal glands, testes, breast, uterus/ovaries
Double-hit lymphoma
Elevated LDH with >1 extranodal site
CNS-IPI score ≥4
Choosing between R-CHOP and pola-R-CHP: For patients with IPI 0–1 (low risk), R-CHOP remains an excellent option with high cure rates. For patients with IPI 2–5, pola-R-CHP is now preferred by NCCN guidelines. Discuss with your oncologist which regimen is best for your specific situation.
Radiation Therapy
Radiation plays a role in DLBCL management in specific situations:
Limited-stage disease (I–II): Consolidation radiation after abbreviated chemotherapy (3–4 cycles of R-CHOP + ISRT is an established approach)
Bulky disease: Consolidation radiation to sites of initially bulky disease, especially if the end-of-treatment PET shows residual uptake
Primary mediastinal B-cell lymphoma (PMBCL): Consolidation radiation after chemoimmunotherapy is used at some centers, though its necessity is debated
Palliative radiation: For symptomatic sites in patients who cannot receive further systemic therapy
Modern radiation uses involved-site radiation therapy (ISRT) rather than older extended-field techniques, limiting the dose and field to reduce late effects.
Response Assessment
Response is assessed primarily by PET/CT scan using the Lugano response criteria and Deauville 5-point scale.
An interim PET scan is often performed after 2–4 cycles to assess early response. A positive interim PET (Deauville 4–5) may prompt biopsy to confirm residual disease and potential change in therapy. In contrast to Hodgkin lymphoma, PET-adapted de-escalation strategies are not well established for DLBCL — most patients complete the planned number of cycles regardless of interim PET results.
Complete metabolic response (Deauville 1–3): Excellent outcome. Observation with periodic follow-up. No further treatment needed.
Partial response or progressive disease (Deauville 4–5): Biopsy recommended to confirm residual lymphoma (PET can have false positives due to inflammation). If confirmed, proceed to second-line therapy.
Supportive Care During Treatment
Patients with large tumor burden (bulky disease, elevated LDH) are at risk for tumor lysis syndrome (TLS) when treatment is started. Allopurinol or rasburicase and aggressive hydration are given preventively before the first cycle.
Granulocyte colony-stimulating factor (G-CSF, filgrastim, or pegfilgrastim) is given after each cycle to reduce the duration and severity of neutropenia (low white blood cells). This reduces the risk of infections and helps maintain dose intensity and cycle timing, which are critical for optimal outcomes in DLBCL.
Rituximab can cause infusion reactions (fever, chills, rigors, hypotension) especially during the first infusion. Pre-medication with acetaminophen, diphenhydramine, and sometimes steroids reduces this risk. Subsequent infusions are faster and usually better tolerated. Subcutaneous rituximab (Rituxan Hycela) is available and reduces infusion time significantly.
Doxorubicin (the “H” in R-CHOP) can cause heart damage (cardiomyopathy). A baseline echocardiogram or MUGA scan is performed before treatment. Patients with pre-existing cardiac disease may need modified regimens. The lifetime cumulative dose of doxorubicin is limited to reduce cardiac risk.
Hepatitis B testing is mandatory before rituximab. Rituximab can cause fatal hepatitis B reactivation in patients with prior exposure. All patients must be tested for HBsAg and anti-HBc before starting treatment. Patients with evidence of prior hepatitis B infection require antiviral prophylaxis (entecavir or tenofovir) throughout treatment and for at least 12 months after the last rituximab dose.
R-CHOP can impair fertility, particularly in younger patients. Sperm banking (for men) and oocyte or embryo cryopreservation (for women) should be discussed BEFORE starting treatment. The urgency of DLBCL treatment means this conversation must happen quickly, ideally at diagnosis.
DLBCL is aggressive and usually cannot wait until after delivery, so treatment during pregnancy is sometimes necessary and is managed jointly by a lymphoma specialist and a maternal-fetal medicine (high-risk obstetrics) team. R-CHOP chemotherapy can generally be given in the second and third trimesters with careful monitoring, and many women have healthy babies. Treatment in the first trimester is avoided where possible because of the risk to the developing baby; options in that situation (including timing of therapy or, rarely, ending the pregnancy) are deeply personal decisions made with your medical team. Rituximab and the anthracycline (doxorubicin) in R-CHOP have specific considerations your team will weigh. If you are pregnant or could become pregnant, tell your team immediately so the plan can be tailored to protect both you and your baby.
Am I receiving R-CHOP or pola-R-CHP, and why was this chosen for me?
How many cycles will I need?
Will I need radiation therapy after chemotherapy?
Am I at risk for CNS relapse, and do I need CNS prophylaxis?
When will I have my interim PET scan, and what will the results mean?
What are the main side effects I should watch for?
Should I receive G-CSF after each cycle?
Has my hepatitis B status been checked?
Should I consider fertility preservation before starting treatment?
Is there a clinical trial available for my situation?
Relapsed and Refractory DLBCL
Approximately 30–40% of DLBCL patients will have disease that either does not respond to first-line treatment (refractory) or returns after initial remission (relapsed). The treatment approach for relapsed/refractory (R/R) DLBCL has been transformed by CAR-T cell therapy and bispecific antibodies.
Historically, the standard approach for R/R DLBCL was:
Salvage chemotherapy: Regimens like R-ICE (rituximab, ifosfamide, carboplatin, etoposide) or R-DHAP (rituximab, dexamethasone, high-dose cytarabine, cisplatin) to achieve a second remission.
Autologous stem cell transplant (auto-SCT): If chemosensitive disease was demonstrated, high-dose chemotherapy followed by re-infusion of the patient’s own stem cells.
This approach cures approximately 30–40% of patients with chemosensitive relapse. However, patients with primary refractory disease or early relapse (within 12 months) have poor outcomes with this strategy.
Since 2020, two major shifts have occurred:
CAR-T in second line: For patients with primary refractory DLBCL or relapse within 12 months, CAR-T cell therapy (axi-cel or liso-cel) is now preferred over salvage chemo + auto-SCT, based on the ZUMA-7 and TRANSFORM trials.
Bispecific antibodies for later lines: Glofitamab and epcoritamab provide effective options for patients who relapse after or are ineligible for CAR-T, avoiding the need for intensive chemotherapy or transplant.
For patients with late relapse (beyond 12 months) who are transplant-eligible, salvage chemo + auto-SCT remains a reasonable option because these patients tend to have more chemosensitive disease.
CAR-T Cell Therapy
CAR-T (chimeric antigen receptor T-cell) therapy is a form of immunotherapy where a patient’s own T cells are collected, genetically modified to recognize and kill lymphoma cells, expanded in a laboratory, and then infused back into the patient.
Product
Brand
Approved Setting
Key Trial
Key Result
Axicabtagene ciloleucel
Yescarta
2nd line (primary refractory or early relapse) and 3rd+ line
CR rate ~32%; durable remissions in responding patients
Leukapheresis: T cells are collected from the patient’s blood (takes 3–4 hours).
Manufacturing: T cells are sent to a laboratory where they are genetically modified to express a chimeric antigen receptor (CAR) targeting CD19. Manufacturing takes 3–5 weeks.
Bridging therapy: While waiting for manufacturing, patients may receive “bridging” therapy (chemotherapy, radiation, or steroids) to control the lymphoma.
Lymphodepleting chemotherapy: A short course of chemotherapy (usually fludarabine + cyclophosphamide) is given 3–5 days before CAR-T infusion to create space for the engineered cells.
CAR-T infusion: The modified T cells are infused back into the patient. The infusion itself takes only about 30 minutes.
Monitoring: Patients are monitored closely for 7–14+ days for serious side effects, particularly cytokine release syndrome (CRS) and neurotoxicity (ICANS).
Cytokine release syndrome (CRS): Occurs in 40–90% of patients. Ranges from mild fever to life-threatening organ dysfunction. Treated with tocilizumab (an IL-6 receptor blocker) and steroids. Most cases are manageable.
Neurotoxicity (ICANS): Immune effector cell-associated neurotoxicity syndrome. Can cause confusion, difficulty speaking, tremors, seizures, or cerebral edema. Treated with steroids. Usually reversible.
Prolonged cytopenias: Low blood counts can persist for weeks to months after CAR-T.
B-cell aplasia: CAR-T cells targeting CD19 also destroy normal B cells, leading to low antibody levels (hypogammaglobulinemia). IV immunoglobulin replacement may be needed.
Infections: Increased infection risk due to cytopenias and immune suppression.
T-cell lymphoma risk: The FDA has identified rare cases of T-cell malignancies (including CAR-positive T-cell lymphomas) occurring after CAR-T therapy. The overall risk appears very low and the benefits of CAR-T generally outweigh this risk, but patients should discuss this with their care team.
Bispecific Antibodies
Bispecific antibodies are a newer class of immunotherapy that redirects the patient’s own T cells to kill lymphoma cells by simultaneously binding CD20 on the lymphoma and CD3 on T cells.
FDA-APPROVED Glofitamab is given as an IV infusion in a step-up dosing schedule (to reduce CRS risk). After a pre-treatment dose of obinutuzumab, glofitamab is given for up to 12 cycles over approximately 8.5 months. A key advantage is that it has a fixed treatment duration — patients who complete treatment and achieve remission stop therapy.
In the NP30179 pivotal trial, the complete remission rate was approximately 39% in heavily pretreated patients. Among complete responders, approximately 78% remained in remission at 18 months.
FDA-APPROVED Epcoritamab is given as a subcutaneous injection (under the skin), which is more convenient than IV infusion. It uses a step-up dosing schedule over the first few weeks, then transitions to every 2 weeks, then monthly. Unlike glofitamab, epcoritamab is currently given until disease progression (no predefined stopping point).
In the EPCORE NHL-1 trial (NCT03625037), the complete remission rate was approximately 38% in heavily pretreated patients.
Cytokine release syndrome (CRS): Occurs in approximately 40–60% of patients, but is predominantly low-grade (Grade 1–2). Managed with step-up dosing, pre-medication, and tocilizumab when needed.
ICANS (neurotoxicity): Less common than with CAR-T, but can occur. Usually low-grade.
Infections: Increased risk due to immune suppression and cytopenias.
Tumor flare: Temporary worsening of symptoms as lymphoma cells are attacked.
Hospitalization: Most centers require 24–48 hour hospitalization for the first full dose to monitor for CRS. Subsequent doses may be given outpatient.
Clinical Trials — Finding and Enrolling
Clinical trials are particularly important in DLBCL because the treatment landscape is evolving rapidly. Trials are available for first-line treatment, relapsed disease, and novel combinations of existing therapies.
Glofitamab + gemcitabine/oxaliplatin vs. R-GemOx (positive, but the US FDA declined the 2nd-line use in 2025; glofitamab alone remains approved for later lines)
Tafasitamab + lenalidomide + R-CHOP vs. R-CHOP — positive Phase 3 (improved progression-free survival, presented June 2026); investigational in 1L, not yet FDA-approved for first-line use
Leukemia & Lymphoma Society (LLS) Clinical Trial Support Center: 1-800-955-4572 — free nurse navigators
Your academic lymphoma center: Many trials are available only at specific centers.
International Access & Regulatory Landscape
DLBCL drug approvals and availability vary significantly by country.
Drug
US FDA
EMA (Europe)
Notes
Pola-R-CHP (Polivy)
2023 (1L DLBCL)
2023
NICE approved; broadly available globally
Axi-cel (Yescarta)
2022 (2L); 2017 (3L+)
Approved (3L+); 2L under review in some jurisdictions
CAR-T access limited in LMIC; manufacturing logistics complex
Liso-cel (Breyanzi)
2022 (2L); 2021 (3L+)
Approved 2022
More widely available in EU than initially
Glofitamab (Columvi)
2023 (R/R 3L+)
2023
Fixed-duration; broader global access expected
Epcoritamab (Epkinly)
2023 (R/R 3L+)
2023
SC administration; wider access in outpatient settings
Loncastuximab tesirine (Zynlonta)
2021 (R/R 3L+)
2022
ADC targeting CD19
Tafasitamab + lenalidomide (Monjuvi)
2020 (R/R, transplant-ineligible)
2021
Role diminished with bispecific antibody availability
CAR-T access: CAR-T cell therapy requires specialized manufacturing and certified treatment centers (REMS programs). It is widely available in the US, EU, and parts of Asia-Pacific, but access remains limited in low- and middle-income countries. Bispecific antibodies may help bridge this access gap as “off-the-shelf” alternatives.
ESMO (Europe): Clinical practice guidelines for DLBCL
BSH (British Society for Haematology): UK-specific guidelines
Lugano Classification (2014): International staging and response criteria
NICE (UK): Technology appraisals for NHS access
LYSA (France): Lymphoma Study Association; major trial group
GeLa/GELA (Germany/France): Landmark DLBCL trials
Health Canada / CADTH: Canadian drug access pathway
Failed & De-Adopted Therapies
Understanding what has not worked helps you evaluate new claims and avoid ineffective treatments.
FAILED The PHOENIX trial (NCT01855750) added ibrutinib (a BTK inhibitor) to R-CHOP for patients with ABC-subtype DLBCL, based on the rationale that ABC-type depends on NF-kB signaling through BTK. Despite strong preclinical rationale, the trial did not show significant improvement in event-free survival for the overall ABC population. Increased toxicity was observed, particularly in older patients. Ibrutinib + R-CHOP is not recommended for DLBCL.
FAILED The ROBUST trial (NCT02285062) tested lenalidomide added to R-CHOP for ABC-type DLBCL. Despite prior phase 2 data suggesting benefit, the phase 3 trial did not meet its primary PFS endpoint. Lenalidomide + R-CHOP is not standard treatment for DLBCL.
FAILED The REMoDL-B trial added bortezomib (a proteasome inhibitor) to R-CHOP for all DLBCL subtypes. While the combination was feasible, it did not improve PFS or OS in any molecular subtype. This demonstrated that targeting the proteasome does not add benefit to standard chemoimmunotherapy in DLBCL.
FAILED Unlike Hodgkin lymphoma, DLBCL generally does not respond well to PD-1 checkpoint inhibitor monotherapy. Response rates are low (~10%) except in specific subtypes such as primary mediastinal B-cell lymphoma or Richter transformation. Checkpoint inhibitors are not recommended as single agents for typical DLBCL.
Why this matters: Multiple attempts to improve on R-CHOP for specific DLBCL subtypes have failed. Pola-R-CHP (POLARIX) is the first and currently only regimen to show a significant improvement over R-CHOP in a randomized trial. Be cautious of claims about unproven additions to standard therapy.
Is my lymphoma primary refractory, early relapse, or late relapse? How does that affect my options?
Am I eligible for CAR-T cell therapy? If so, which product is recommended?
How long is the CAR-T manufacturing process, and what will I receive as bridging therapy?
Should I receive a bispecific antibody instead of or after CAR-T?
Am I still a candidate for autologous transplant?
What are the risks of CRS and neurotoxicity with the recommended treatment?
Is there a clinical trial I should consider?
Has my lymphoma been re-biopsied to confirm it is still DLBCL and to check for transformation?
class="content-section" data-stage="resources">
Specialty Centers
DLBCL first-line treatment (R-CHOP or pola-R-CHP) can often be managed by a community oncologist experienced in lymphoma. However, for relapsed/refractory disease, CAR-T therapy, bispecific antibody initiation, and clinical trial access, referral to an academic lymphoma center is strongly recommended.
No endorsement. Listing a center here does not constitute an endorsement or recommendation. Trouvera has no financial relationship with any medical center listed unless explicitly disclosed. Patients should evaluate centers based on their own needs and in consultation with their medical team.
Huntsman Cancer Institute (HCI) — University of Utah
NCI-designated Comprehensive Cancer Center with dedicated lymphoma program and CAR-T certified center
Location: 2000 Circle of Hope Dr, Salt Lake City, UT 84112 Phone: 801-585-0303 Programs: Lymphoma Program, Blood & Marrow Transplant Program, CAR-T cell therapy (certified for axi-cel and liso-cel), clinical trials portfolio for DLBCL including bispecific antibodies and novel combinations.
Why it matters. HCI is the only NCI-designated Comprehensive Cancer Center in the Mountain West region. Its lymphoma and BMT programs offer the full range of DLBCL treatments including CAR-T cell therapy and access to clinical trials.
University of Utah Health — Hematology
Phone: 801-581-2121 Services: Hematology-oncology, lymphoma evaluation and treatment, referral coordination with HCI for transplant and CAR-T.
Intermountain Health
Phone: 801-442-2000 Programs: Hematology-oncology network across Utah and the Intermountain West. R-CHOP and pola-R-CHP administration. Referral to HCI or other centers for CAR-T and clinical trials.
Mayo Clinic Arizona
Location: 5777 E Mayo Blvd, Phoenix, AZ 85054 Phone: 480-301-8000 Programs: Lymphoma program, CAR-T cell therapy, BMT, clinical trials.
University of Colorado Cancer Center
Location: Anschutz Medical Campus, Aurora, CO 80045 Phone: 720-848-0000 Programs: NCI-designated Comprehensive Cancer Center. Lymphoma program with active DLBCL clinical trials. CAR-T capable.
Referral routing. Community oncologists across Utah can administer R-CHOP/pola-R-CHP locally. For CAR-T evaluation, bispecific antibody initiation, or clinical trials, refer to Huntsman Cancer Institute (801-585-0303). For transplant-eligible relapse at Intermountain facilities, coordinate with HCI or the Intermountain BMT team.
Information verified May 2026. Availability changes — confirm with each institution directly.
MD Anderson Cancer Center
Location: Houston, TX · Phone: 877-632-6789
Major lymphoma program with one of the largest CAR-T experiences worldwide. Extensive DLBCL clinical trial portfolio.
Memorial Sloan Kettering Cancer Center
Location: New York, NY · Phone: 212-639-2000
Lymphoma service with CAR-T, bispecific antibody programs, and extensive clinical trials.
Dana-Farber Cancer Institute
Location: Boston, MA · Phone: 617-632-3000
Harvard-affiliated. Large lymphoma program, CAR-T center, and novel agent trials.
Fred Hutchinson Cancer Center
Location: Seattle, WA · Phone: 206-667-5000
Pioneered cellular therapies. High-volume transplant center with active lymphoma CAR-T research.
Mayo Clinic Rochester
Location: Rochester, MN · Phone: 507-538-3270
Comprehensive lymphoma and BMT program. CAR-T certified. National reach.
City of Hope
Location: Duarte, CA · Phone: 626-256-4673
NCI-designated Comprehensive Cancer Center. High-volume BMT and CAR-T center.
Moffitt Cancer Center
Location: Tampa, FL · Phone: 888-663-3488
NCI-designated Comprehensive Cancer Center. Lymphoma and CAR-T programs.
University of Pennsylvania / Abramson Cancer Center
Location: Philadelphia, PA · Phone: 215-662-4000
Developed tisagenlecleucel (Kymriah). Pioneer in CAR-T cell therapy research.
VA Hematologic Malignancies Care
The VA system provides lymphoma care through its network of medical centers. For CAR-T therapy and transplant, the VA partners with academic centers through community care arrangements.
VA Salt Lake City (George E. Wahlen VAMC): 801-582-1565 VA Cancer Care:cancer.va.gov VA Community Care: 1-877-881-7618
Princess Margaret Cancer Centre, Toronto
Phone: 416-946-4501
One of the largest lymphoma and BMT programs in North America. Active DLBCL clinical trials.
BC Cancer — Vancouver Centre
Phone: 604-877-6000
Provincial lymphoma and BMT referral center for British Columbia.
Tom Baker Cancer Centre, Calgary
Phone: 403-944-1110
Alberta’s BMT program. Lymphoma treatment and clinical trials.
Leukemia & Lymphoma Society of Canada:llscanada.org Canadian Cancer Society helpline: 1-888-939-3333 Lymphoma Canada:lymphoma.ca
International Centers of Excellence for DLBCL
The Christie NHS Foundation Trust, Manchester, UK: Major UK NCRI lymphoma trial center
Hôpital Saint-Louis, Paris, France: LYSA trial center; lymphoma research leader
University of Milan / Fondazione IRCCS, Italy: European lymphoma research center
Peter MacCallum Cancer Centre, Melbourne, Australia: ALLG trial center; CAR-T program
National Cancer Center Hospital, Tokyo, Japan: JCOG trial center; early access to novel therapies
Samsung Medical Center, Seoul, South Korea: Asian lymphoma trial hub
Caregiver Guidance
Caring for someone with DLBCL involves navigating treatment cycles, managing side effects, and providing emotional support through an uncertain but often hopeful journey.
Treatment is typically outpatient. R-CHOP and pola-R-CHP are given in infusion centers over several hours. Plan for full-day appointments on treatment days.
Days 7–14 after each cycle are the riskiest. Blood counts drop to their lowest point (nadir), increasing infection risk. Monitor for fever (≥100.4°F / 38.0°C) and call the oncologist immediately if it occurs.
Nausea management has improved greatly. Modern anti-nausea medications prevent most severe nausea. Make sure prescribed anti-nausea medications are taken on schedule, not just when symptoms start.
Hair loss is expected. It typically begins 2–3 weeks after the first cycle and is reversible after treatment ends.
Expect to stay near the treatment center for 4–6 weeks. Most CAR-T centers require patients to remain within a certain distance (often 30–60 minutes) for at least 4 weeks after infusion for close monitoring.
A caregiver is required. CAR-T centers require a designated caregiver to be present 24/7 for the first 2–4 weeks after infusion.
Know the signs of CRS and neurotoxicity: fever, rapid heart rate, low blood pressure, confusion, difficulty speaking, tremors, seizures. Report any of these immediately.
Recovery is gradual. Most patients feel better within 1–3 months, but immune recovery can take 6–12 months or longer.
Connect with other DLBCL families. The Lymphoma Research Foundation (LRF) at 1-800-500-9976 offers peer support programs. LLS provides similar resources at 1-800-955-4572.
Caregiver burnout is common. Accept help from friends and family. Use social work and psychology services available at cancer centers.
The uncertainty is the hardest part. Treatment may be going well, but the waiting for scan results and the fear of relapse are genuinely difficult. This is normal.
Glossary
ABC subtype
Activated B-cell subtype of DLBCL. Tends to have worse outcomes with R-CHOP than GCB subtype.
Autologous transplant
Stem cell transplant using the patient’s own cells. Used in chemosensitive relapsed DLBCL.
Bispecific antibody
An antibody engineered to bind two targets simultaneously (CD20 on lymphoma + CD3 on T cells), redirecting immune cells to attack cancer.
CAR-T
Chimeric antigen receptor T-cell therapy. Patient’s T cells are genetically modified to recognize and kill CD19-expressing lymphoma cells.
CD19
A protein on the surface of B cells. Target for CAR-T therapy and loncastuximab tesirine.
CD20
A protein on the surface of B cells. Target for rituximab and bispecific antibodies (glofitamab, epcoritamab).
Complete remission (CR)
No detectable disease on PET/CT scan (Deauville 1–3). Does not always mean cure, but is the best possible outcome.
CRS
Cytokine release syndrome. A potentially serious immune reaction to CAR-T or bispecific antibodies. Treated with tocilizumab and steroids.
Deauville score
A 5-point scale used to interpret PET scans. Scores 1–3 = good response; 4–5 = active disease.
DLBCL
Diffuse large B-cell lymphoma. The most common type of aggressive non-Hodgkin lymphoma.
Double-hit
Lymphoma with rearrangements of both MYC and BCL2 (and/or BCL6). Now classified as high-grade B-cell lymphoma. Requires intensified treatment.
Double-expresser
Lymphoma that overexpresses both MYC and BCL2 protein by IHC but without gene rearrangements. Worse prognosis with R-CHOP.
FISH
Fluorescence in situ hybridization. A test to detect specific gene rearrangements (MYC, BCL2, BCL6).
GCB subtype
Germinal center B-cell subtype of DLBCL. Better outcomes with R-CHOP than ABC subtype.
ICANS
Immune effector cell-associated neurotoxicity syndrome. A side effect of CAR-T and bispecific antibodies. Usually reversible.
IPI
International Prognostic Index. A scoring system (0–5) predicting outcomes in DLBCL based on age, stage, LDH, ECOG, and extranodal sites.
Lugano Classification
The current staging system for lymphoma, based on Ann Arbor staging with PET/CT integration.
PET/CT
Positron emission tomography/computed tomography. The standard imaging study for staging and response assessment in DLBCL.
Rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone. The standard first-line treatment for DLBCL for 20+ years.
Rituximab
An anti-CD20 monoclonal antibody. The “R” in R-CHOP. Revolutionized lymphoma treatment when added to CHOP chemotherapy.
Sources and Further Reading
This guide draws on published medical literature, clinical trial records, and the work of physicians treating DLBCL across multiple countries. Key sources are listed below.
Lymphoma Research Foundation (LRF) (lymphoma.org) — Patient education, helpline (1-800-500-9976)
Leukemia & Lymphoma Society (LLS) (lls.org) — Patient education, financial assistance, clinical trial support (1-800-955-4572)
National Cancer Institute (NCI) (cancer.gov) — Comprehensive lymphoma information
Key Guideline and Trial References
Lugano Classification: Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
POLARIX: Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351–363. (NCT03274492)
ZUMA-7: Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640–654. (NCT03391466)
TRANSFORM: Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma. Lancet. 2022;399(10343):2294–2308. (NCT03575351)
EPCORE NHL-1: Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3×CD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma. J Clin Oncol. 2023;41(12):2238–2247. (NCT03625037)
JULIET: Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56. (NCT02445248)
External links notice: Links to government agencies, academic institutions, and private organizations are provided for informational convenience. Linking does not constitute endorsement by Trouvera, and we cannot attest to the accuracy of external content. You will be subject to the destination site’s privacy policy when you leave this site.
What This Guide Does Not Know
An honest guide names its own limits:
This guide cannot diagnose, stage, or treat anyone. It does not know your subtype, IPI score, comorbidities, or personal preferences. Only your medical team can build an actual treatment plan.
DLBCL treatment is evolving rapidly. New approvals and guideline updates occur frequently. Time-sensitive facts should be re-verified with your team, on FDA.gov, and on ClinicalTrials.gov.
Drug approvals and availability vary by country. CAR-T access is limited in many countries. This guide focuses primarily on FDA-approved therapies.
Individual outcomes cannot be predicted. IPI scores describe populations, not individuals. Two patients with the same score can have very different courses.
A final word. DLBCL is a curable cancer. That is the single most important fact in this guide. Approximately 60% of patients are cured with first-line treatment, and even for those who relapse, CAR-T cell therapy and bispecific antibodies are producing durable remissions that were not possible a few years ago. Get to a lymphoma specialist. Get your pathology reviewed. Ask about trials. Use the resources in this guide. You are not alone. There is genuine reason for hope.
Important Safety Warnings: CAR-T Cell Therapy
CAR-T cell therapies (axicabtagene ciloleucel/Yescarta, lisocabtagene maraleucel/Breyanzi, tisagenlecleucel/Kymriah) are transformative treatments for relapsed/refractory DLBCL but carry life-threatening risks requiring treatment at certified centers.
Boxed Warning: Cytokine Release Syndrome (CRS) and Neurological Toxicity (ICANS):
Cytokine Release Syndrome (CRS): CAR-T cells cause massive immune activation as they kill cancer cells. This triggers a systemic inflammatory response (CRS) that can be severe or fatal. Symptoms include high fever, chills, low blood pressure, difficulty breathing, and multi-organ dysfunction. CRS typically occurs within 1–14 days of infusion. It is treated with tocilizumab (an IL-6 inhibitor) and corticosteroids. Grade 3–4 CRS requires intensive care. You will be monitored in the hospital for at least several days after CAR-T infusion specifically for CRS.
Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): CAR-T can cause severe and potentially fatal neurological toxicity including confusion, difficulty speaking, encephalopathy, tremors, agitation, seizures, and cerebral edema. ICANS can occur simultaneously with or after CRS. It typically peaks 1–2 weeks post-infusion. Treatment requires ICU-level monitoring and high-dose corticosteroids.
CAR-T must only be administered at certified, FDA-authorized treatment centers with on-site ICU capability, specific staff training, and emergency tocilizumab supply. You cannot receive CAR-T at a facility that is not REMS-certified for these products.
Mandatory monitoring period: Patients must remain within 2 hours of the certified treatment center for at least 4 weeks after infusion (manufacturer requirement). Do not travel away from the treatment area during this period.
Driving restriction: Patients may not drive or operate heavy machinery for at least 8 weeks after CAR-T infusion due to ICANS risk.
Prolonged cytopenias and infection: CAR-T causes long-lasting suppression of B cells and immune function. Severe hypogammaglobulinemia (low antibody levels) requiring IVIG replacement, and prolonged neutropenia increasing infection risk, are expected. PCP prophylaxis, antiviral prophylaxis, and avoidance of live vaccines are required for months after CAR-T.